^
Association details:
| Biomarker: | AR-V7 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | cabazitaxel (Microtubule inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs
Excerpt:
...Circulating tumor cell (CTC) response rate`Prostate specific antigen (PSA) change from baseline`Maximum Prostate specific antigen (PSA) decrease`Progression-free survival`Overall survival`grade 3-4 adverse events and serious adverse events (SAEs)`Cabazitaxel concentration in the blood (measured in ng/mL)`Total systemic exposure to cabazitaxel (measured in mg/m2)`AR-V7 mRNA expression as well as mRNA expression of other splice variants in CTCs indicated as absent (-) or present (+) on a per-patient basis...
Trial ID:
Source:
Title:
Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)
Excerpt:
......
Trial ID:
Less C2 evidence
Source:
Title:
Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel
Published date:
01/31/2022
Excerpt:
Baseline CTC biomarkers may be prognosticators for cabazitaxel-treated mCRPC patients. Cabazitaxel at lower (20 mg/sqm) dose was associated with poorer outcomes in AR-V7 positive patients compared to AR-V7 negative patients in a post hoc subgroup analysis....Among these patients, 8 (18%) had AR-V7 CTC expression....In patients treated with cabazitaxel 20 mg/sqm, median OS was shorter in AR-V7 positive than negative patients (6.6 versus 14 months, HR=3.46, 1.47–8.17], p=0.004)...the correlation between AR-V7 expressions and worse outcome was significantly associated with the initial reduced dose of cabazitaxel for OS (p = 0.056).
DOI:
https://doi.org/10.1186/s12916-022-02244-0
Trial ID:
